Part I Basic Science and Experimental Studies on Stem Cell
Mobilization
1 Preclinical Experience with AMD3100 for Mobilization
of Hematopoietic Stem and Progenitor Cells ................... 3
Hal E. Broxmeyer
2 Molecular Pharmacology of CXCR4 Inhibition .................. 23
Anne Steen and Mette Marie Rosenkilde
3 Combination Strategies for Stem Cell Mobilization
Targeting CXCR4 and SIP Receptors ........................... 37
Nadia Harun, Kenneth Bradstock, and Linda J. Bendall
4 Should We Stay or Should We Go Now? Cell Adhesion and
Mobilization Pathways of Hematopoietic Cells ................ 55
Eike C. Buss and Anthony D. Ho
5 Role of the CXCR4/CXCL12 Axis in Hematopoietic
Stem Cell Trafficking ....................................... 71
Amnon Peled and Arnon Nagler
Part II Clinical Studies on Stem Cell Mobilization
6 Early Studies of AMD3100/Plerixafor in Healthy Volunteers ... 89
David C. Dale and W. Conrad Liles
7 The Current Role of Plerixafor in Stem Cell Mobilization
for Hematopoietic Stem Cell Transplantation ................ 103
Amy R. MacKenzie, Matias E. Valsecchi, and Neal
Flomenberg
8 Experience with Apheresis Procedures After Plerixafor
Mobilisation ............................................... 133
Kenneth Douglas
9 Influence of Different Stem Cell Mobilization Strategies
on Graft Composition and Outcome of Autologous
or Allogeneic Transplantation .............................. 165
Stefan Fruehauf and Guido Tricot
10 Relevance and Clinical Implications of Tumor Cell
Mobilization in Autologous Transplantation of Multiple
Myeloma and Non-Hodgkin's Lymphoma ......................... 201
Stefan Fruehauf, Anthony D. Ho, Jessie Hanrahan, Frank
J. Hsu, and John F. DiPersio
11 Plerixafor: Data from the Compassionate Use Program ........ 221
Maximilian M. Fresen and Kai Hiibel
12 Stem Cell Mobilization with Chemomobilization Plus
Plerixafor in Hard-to-Mobilize Patients: The Experience
at Kuopio University Hospital, Finland ..................... 235
Esa Jantunen and Tapio Nousiainen
13 Blood Stem Cell Mobilization in Solid Tumors: Experience
with Plerixafor and Alternative Ways of Hematopoietic
Stem Cell Mobilization ..................................... 247
Guido Kobbe and Rainer Haas
14 Mobilization with Chemotherapy + G-CSF + Plerixafor
in Europe: The Italian Experience .......................... 263
Roberto M. Lemoli and Alessandra D' Addio
15 Experience with Plerixafor in Poor Mobilizers .............. 277
Catherine H. Roberts and John M. McCarty
16 CXCR4 Antagonists .......................................... 303
Klaus Dembowsky, Barbara Romagnoli, Johann Zimmermann,
Eric Chevalier, Christian Ludin, and Daniel Obrecht
Part III CXCR4 Antagonists for Treatment of Leukemias and
Solid Tumors
17 Application of CXCR4 Inhibitors in Leukemia ................ 335
George Ansstas, Fazia Mir, Michael P. Rettig,
Mark Schroeder, Linda Eissenberg, and John F. DiPersio
18 CXCR4 Antagonists for the Treatment of CML ................. 351
Anupriya Agarwal, Thomas O'Hare, and Michael Deininger
19 Targeting CXCR4 in Chronic Lymphocytic Leukemia:
Preclinical Rationale and Early Clinical Experience ........ 369
Jan A. Burger
20 CXCR4-Blockade for Treatment of Breast Cancer .............. 387
Patricia A. Cronin and H. Paul Redmond
21 Molecular Imaging of CXCR4 Receptor Expression in Tumors ... 399
Lauren E. Woodard and Sridhar Nimmagadda
Part IV Novel Applications
22 Potential Use of CXCR4 Antagonists to Mobilize
Endothelial and Mesenchymal Stem Cells ..................... 423
Sara M. Rankin
23 Strategies to Enhance Hematopoietic Stem Cell
Engraftment Following Transplantation ...................... 439
Yubin Kang and Nelson J. Chao
24 Mobilization for Gene Therapy .............................. 457
Andre Larochelle and Cynthia E. Dunbar
Index ......................................................... 487
|
